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OBJECTIVES: To determine factors affecting costs (based on
main payor’s perspective) and length of hospital stay in patients
hospitalised for CAP in Germany. METHODS: Within an inter-
national study (Germany, France, Japan, USA), 12 months’ ret-
rospective data (July 2001 to June 2002) of 603 CAP-patients
(14 sites) were collected by chart review in Germany and
analysed for factors likely to affect costs and length of hospital-
isation (linear- and Cox-PH-regressions, respectively). Costs
were calculated from the perspective of the German public health
insurance (GKV) for the year 2001, based on daily fees per ward
minus patient deductible/co-payment. RESULTS: Patients (mean
age 63 years) were predominantly male (58%), living with family
(64%), retired (56%) and publicly insured (88%); 82% had any
prior disease, 43% prior respiratory diseases. At hospitalisation,
mainly due to worsening of pneumonia (55%), the mean modi-
ﬁed FINE score was 90 (low/moderate risk). A total of 57% of
patients had low (classes I, II, III), 23% moderate (class IV) and
20% high (class V) modiﬁed FINE scores. Besides antibiotics,
concomitant medications were mostly cough/cold suppressants.
The median duration of hospitalisation was 12 days. Costs were
calculated to amount to an average of 3892€ per hospital stay.
Extrapolation to population levels results in almost 1000€
million CAP-related costs per year. Factors associated with both
higher costs and prolonged hospital stays (p < 0.05) included
combination/multiple antibiotic treatment and inappropriate
antibiotic treatment (i.e. antibiotics given not likely to/did not
cover CAP-related pathogens), current smoking status and non-
teaching hospital. Multimorbid patients were likely to incur
higher costs. Increasing age was correlated with longer hospital
stays. CONCLUSIONS: In Germany, treatment of patients hos-
pitalised for CAP is costly from the payor’s perspective and
amounts to almost 1000€ million per year. Appropriate antibi-
otic treatment was associated with lower costs and shorter hos-
pital stays.
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OBJECTIVES: To evaluate the clinical outcomes and direct costs
associated with the treatment of severe sepsis in intensive care
units (ICUs) in Poland. METHODS: Web-based Severe Sepsis
Registry was founded to collect clinical data and information on
resources used for severe sepsis patients management in Poland.
Patients were hospitalized in 108 ICUs from 1st April 2003 to
2nd April 2004. As payer’s perspective was adapted only direct
medical ICUs costs were analyzed and encompassed: ﬁxed costs
of ICU stay, organ support, medical procedures and drugs. Unit
costs were calculated using drugs retail prices, hospital accounts
systems data and medical procedures tariffs contracted by
National Health Found. Costs are expressed in PLN (1PLN =
0.4808 Euro PPP’2003). RESULTS: A total of 1168 severe sepsis
patients were registered. The mean ICU length of stay was 18.99
days (95% CI: 17.6; 20.4). Total individual treatment cost was
estimated at 53,799 PLN (25,867€), 95%CI: 50,291–57,307
PLN (24,180–27,553€). The mean ICU daily cost amounted to
2833 PLN (1362€). The main costs components included: ICU
stay ﬁxed costs (76.45%), antibiotics (9.32%), (activated)
drotrecogin alfa (5.34%), ATIII (2.66%), mechanical ventilation
(2.25%) and renal replacement therapy (1.63%). The ICU sur-
vival rate amounted to 45.1%, thus the mean cost per one sur-
vivor equaled 119 236 PLN (57,329€). CONCLUSIONS: Severe
sepsis is associated with poor prognosis and substantial treat-
ment cost mainly resulting from high ﬁxed cost of ICU stay.
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OBJECTIVES: To assess the cost-effectiveness of drotecogin alfa
activated (DAA) compared to standard therapy (ST) in severe
sepsis in Poland. METHODS: Data on clinical effectiveness and
resources used were derived from Polish Severe Sepsis Registry
(SSR) of patients hospitalized in 108 ICUs from 1st April 2003
to 2nd April 2004. The effectiveness was deﬁned as the ICU stay
survival and life year gained. Only direct medical ICUs costs
were analyzed. Unit costs were calculated using drugs retail
prices, hospital accounts systems data and medical procedures
tariffs contracted by National Health Found. The cost-effective-
ness was assessed based on raw survival rates and mean treat-
ment costs for the DAA and ST groups as documented in SSR.
Additionally regression model on effectiveness and associated
costs was constructed to control for case-mix. Costs are
expressed in PLN (1PLN = 0.4808€ PPP’2003). RESULTS: The
rate of ICUs survival amounted to 61% and 44% for the DAA
and ST group, respectively. The corresponding mean costs
amounted to 98,987 PLN (47,593€) and 49,568 PLN (23,832€).
Based on raw data from SSR the additional cost per one death
avoided with DAA was calculated on 284,557 PLN (136,815€).
In regression model DAA was found to signiﬁcantly increase the
survival rate (OR = 2.651; 95%CI: 1.67–4.21) resulting in 4.93
(95%CI: 2.68–6.96) life years gained per patient. Thus the addi-
tional cost per one death avoided and cost per life year gained
with DAA amounted to 183,019 PLN (87,996€) and 7487 PLN
(3600€), respectively. CONCLUSIONS: DAA is cost-effective in
severe sepsis treatment.
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OBJECTIVES: In adults with CHC, peginterferon alfa-2a (40
KD)/ribavirin obtains a higher rate of sustained virological
response (SVR) than interferon alfa-2b/ribavirin, in both geno-
types 1 and 2/3 and high and low viral loads. However, it is still
unproven whether this increase is cost-effective from the per-
spective of the National Health Service (NHS)in the UK.
METHODS: We constructed a 7-stage Markov model in which
cohorts of hepatitis C virus (HCV) genotype 1 and 2/3 patients
received peginterferon alfa-2a (40KD)/ribavirin or interferon
alfa-2b/ribavirin for 48 and 24 weeks, respectively, and were fol-
lowed for their expected lifetime. The SVRs to peginterferon
alfa-2a (40KD)/ribavirin and interferon alfa-2b/ribavirin were
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46% and 36% for HCV genotype 1 and 76% and 61% for geno-
type 2/3. The impact of predictability testing at 12 and 24 weeks
on the cost-effectiveness ratio was explored in the model. Quality
of life and costs were based on literature and on estimated UK
treatment patterns, respectively. Costs were discounted at 6%
and beneﬁts at 1.5%. RESULTS: In genotype 1 patients, pegin-
terferon alfa-2a (40KD)/ribavirin increases quality-adjusted life
expectancy (QALY) by 0.43 years compared to interferon alfa-
2b/ribavirin. The incremental cost per QALY gained is £5596.
In genotype 2/3 patients, peginterferon alfa-2a (40KD)/ribavirin
increases QALY by 0.65 years and is cost saving (dominant) to
the NHS. The incremental cost-effectiveness ratio for all geno-
types was £914. At a cost effectiveness threshold of £30,000
probabilistic sensitivity analysis demonstrated peginterferon
alfa-2a was the cost effective treatment strategy in 96% of the
simulations. CONCLUSIONS: In the UK setting, peginterferon
alfa-2a (40KD)/ribavirin is cost-effective compared with con-
ventional interferon alfa-2b/ribavirin for treatment of naive
adults with CHC in genotype 1 patients and a cost-saving/dom-
inant therapy in genotype 2/3 patients.
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OBJECTIVES: There are no studies carried out to date compar-
ing the cost of systemic fungal infection treatment with voricona-
zole and caspofungin. The aim of the study was to estimate the
in-hospital cost of voriconazole versus caspofungin, plus oral
continuation therapy (OCT), for the treatment of invasive
Candida and Aspergillosis infections in Spain. METHODS: A
cost-minimization analysis model was performed from the hos-
pital perspective in year 2004, as the same efﬁcacy was assumed.
Data on duration of treatment (intravenous + oral) and weight
of patients were obtained from a local study: The Fungcost study.
The incidence of drug-related adverse events was obtained from
published clinical trials. Only direct cost for each episode were
considered; medications (injectable and oral) at their hospital
selling prices, the cost stemming from a drug-related adverse
reactions treatment; and administration costs. Oral voriconazole
was considered as the OCT for voriconazole arm, and oral ﬂu-
conazol or itraconazol for caspofungin arm. Mean expected cost
and incremental cost were calculated. Univariate and bivariate
sensitivity analysis were carried out varying patient’s weight 
and intravenous treatment duration. RESULTS: The mean cost
expected per episode (mean weight 68.6Kg) was 6302.97€ (cost
of intravenous treatment 5798.33€) for voriconazole, and
7487.29€ (6982.65€) for caspofungin in the treatment of inva-
sive aspergillosis, with an incremental cost of 1184.32€. The
treatment of candidiasis showed a mean costs of 6154.82€ (cost
of intravenous treatment 5951.14€) and 7182.71€ (7169.49€),
respectively, with an incremental cost of 1027.89€. Results were
robust to any intravenous duration of treatment, and sensitive
to an increase of patient’s weight above 103.3Kg in aspergillo-
sis and 101.1Kg in candidiasis. CONCLUSIONS: Using costs
and treatments patterns of fungal infections in Spain, voricona-
zole is more cost-effective than caspofungin in the treatment 
of invasive candidiasis and aspergillosis for patients below
101.1/103.3 kilograms, respectively.
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OBJECTIVES: To estimate costs and beneﬁts of a preventive
anti-inﬂuenza vaccination in a group of employees of ULSS 17
(an public health care district), in order to deﬁne a scheme of
cost-beneﬁt analysis to be used for other strategies of vaccina-
tion and in other contexts. METHODS: In an observational
study conducted from December 2002 to April 2003, 107
employees (about 5% of the whole staff of ULSS 17), who vol-
untarily underwent the vaccination, were compared with 107
non-vaccinated employees working in the same context and
matched for age, gender and working category. The outcome was
evaluated by checking records from the personnel department
about absence from work and related causes, including inﬂuenza.
Costs and beneﬁts of the anti-inﬂuenza vaccination from the
ULSS point of view were subsequently calculated. RESULTS:
Among vaccinated people absences from work were 23% less
than among non-vaccinated and working days lost were 30%
less than non vaccinated employees. The ratio between the ben-
eﬁts of the vaccination strategy (less working days lost) and its
cost was 4.2. The convenience emerges also through the sensi-
tivity analysis, which took in consideration the mean cost of a
working day for the enrolled employees, it showed that the cost-
beneﬁt ratio range from 4.5 to 11.7. CONCLUSIONS: The
results of this study suggest that the implementation of the anti-
inﬂuenza vaccination strategy in ours sample of working people
was cost saving. The cost-beneﬁt analysis used in this study could
also be used for other vaccination strategy and in other contexts.
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OBJECTIVE: In our study we aimed to assess and compare the
cost-effectiveness of sepsis treatment with and without Activated
Protein C in Hungary for the year 2002. METHODS: To calcu-
late the average efﬁciency of treatment of a septic patient in ICU
in Hungary we constructed a model. This model was made up
of three parts. In the ﬁrst part, we deﬁned a septic patient cohort
based on the age and gender distribution of all the septic cases
treated in ICU in Hungary in 2001. This patient cohort entered
into the second part of the model where we developed a time
dependent Markov model to describe and analyse the route of
Hungarian septic cases through a 28-day-long period. We
deﬁned three Markovian states: survival in ICU, leaving ICU or
the hospital alive, and death in or out of ICU. Transfer proba-
bilities were deﬁned for each of the 28 days on the basis of data
collected for all septic events treated in ICUs in Hungary in 2001.
In the Activated Protein C (Xigris®) treatment arm the transfer
probabilities of the above-described model was modiﬁed on the
basis of results of a clinical study. In the third phase, patients’
life-long survival was modelled based on the average age-speciﬁc
life expectancy of the Hungarian. Survival of the septic patients
was corrected by a factor of 0.51 taken from the international
literature. Efﬁciency was calculated from societal viewpoint.
RESULTS: Average cost-effectiveness of sepsis treatment was
